China advances CasY7 gene editing to bypass US CRISPR-Cas9 patent landscape

Chinese researchers are prioritizing the development of CasY7, an AI-assisted gene editing tool, to circumvent potential multi-billion dollar patent litigation associated with US-held CRISPR-Cas9 intellectual property. This shift reflects a broader strategic effort to achieve technological autonomy in biotechnology and mitigate legal risks in international research collaboration.